Abstract
Carvedilol is a nonselective β-adrenoceptor blocker with multiple pleiotropic actions. A recent clinical study suggested that carvedilol may be superior to other β-adrenoceptor blockers in the treatment of heart failure. Despite numerous investigations, the underlying mechanisms of carvedilol on improving heart failure are yet to be fully established. The purpose of this study is to clarify the pleiotropic effect of carvedilol on cytosolic and mitochondrial calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. Carvedilol (10 μM), but not metoprolol (10 μM), reduced H2O2 (100 μM)-induced apoptosis in neonatal rat cardiomyocytes. During the process, changes in cytosolic calcium concentration ([Ca2+]i) and mitochondrial calcium concentration ([Ca2+]m) and mitochondrial membrane potential (ΔΨm) were measured by fluorescent probes [Fluo-3/acetoxymethyl ester (AM), Rhod-2/AM, and tetramethylrhodamine ethyl ester, respectively] and imaged by laser confocal microscopy. The results showed that H2O2 caused [Ca2]m overload first, followed by [Ca2+]i overload, leading to ΔΨm dissipation and the induction of apoptosis. Carvedilol (10 μM) significantly delayed these processes and reduced apoptosis. These effects were not observed with other β-adrenoceptor blockers (metoprolol, atenolol, and propranolol) or with a combination of the α (phentolamine)- and the β-adrenoceptor blocker. The antioxidant N-acetyl-l-cysteine (NAC, 5 mM) and the combination of NAC and propranolol (10 μM) showed an effect similar to that of carvedilol. Therefore, the effect of carvedilol on H2O2-induced changes in [Ca2+]m, [Ca2+]i, and ΔΨm is independent of α- and β-adrenoceptors but is probably dependent on the antioxidant effect.
Footnotes
-
This study was partly supported by Research Grant 13670715 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.099903.
-
ABBREVIATIONS: ΔΨm, mitochondrial membrane potential; [Ca2+]m, mitochondrial calcium concentration; [Ca2+]i, cytosolic calcium concentration; NAC, N-acetyl-l-cysteine; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; FITC, fluorescein isothiocyanate; AM, acetoxymethyl ester; TMRE, tetramethylrhodamine ethyl ester; MTG, mitochondrial tracker green; BAPTA-AM, 1,2-bis-(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid-acetoxymethyl ester.
- Received December 21, 2005.
- Accepted April 10, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|